SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $7.68 and traded as high as $7.91. SOPHiA GENETICS shares last traded at $7.86, with a volume of 918,997 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, October 15th. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday, October 12th. Finally, BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Price Performance

The business has a 50-day simple moving average of $7.68 and a 200 day simple moving average of $6.01. The firm has a market cap of $659.38 million, a P/E ratio of -7.21 and a beta of 1.09. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.16 and a current ratio of 2.29.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The business had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $24.03 million. SOPHiA GENETICS had a negative return on equity of 128.69% and a negative net margin of 89.18%. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.94 earnings per share for the current fiscal year.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, Director Kathy L. Hibbs sold 6,250 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $8.68, for a total transaction of $54,250.00. Following the transaction, the director directly owned 103,242 shares of the company’s stock, valued at approximately $896,140.56. The trade was a 5.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Philippe Menu sold 7,394 shares of the business’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22. Following the transaction, the insider owned 200,993 shares in the company, valued at $1,634,073.09. This represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 157,162 shares of company stock valued at $1,270,334 over the last 90 days. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently added to or reduced their stakes in the company. Landscape Capital Management L.L.C. purchased a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $1,030,000. Royce & Associates LP raised its stake in SOPHiA GENETICS by 15.0% during the third quarter. Royce & Associates LP now owns 3,887,743 shares of the company’s stock valued at $32,579,000 after buying an additional 506,007 shares during the last quarter. Sowell Financial Services LLC purchased a new position in SOPHiA GENETICS during the third quarter valued at $2,865,000. Maven Securities LTD purchased a new position in SOPHiA GENETICS during the second quarter valued at $866,000. Finally, AXQ Capital LP bought a new stake in SOPHiA GENETICS in the second quarter worth $119,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.